Trident Texofab Ltd
NSE: BSE: 540726
₹49.46
(4.99%)
Fri, 15 May 2026, 08:17 pm
Market Cap741.69M
PE Ratio22.86
Dividend0
Process Industries
Textiles
24.5KTrident Texofab Analysis
dividend
- Dividends paid are well covered by earnings (2.2x coverage).
- Trident Texofab's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Trident Texofab has only been paying a dividend for 2 years, and since then there has been no growth.
- Whilst dividend payments have been stable, Trident Texofab has been paying a dividend for less than 10 years.
- Trident Texofab's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Trident Texofab is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Trident Texofab is profitable, therefore cash runway is not a concern.
- Trident Texofab is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 2x debt.
- Trident Texofab's cash and other short term assets cover its long term commitments.
- Operating cash flow is negative therefore debt is not well covered.
- The level of debt compared to net worth has increased over the past 5 years (158% vs 169.6% today).
- Interest payments on debt are not well covered by earnings (EBIT is 1.9x annual interest expense, ideally 3x coverage).
- Trident Texofab's level of debt (169.6%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Trident Texofab board of directors is about average.
- Hardik's remuneration is lower than average for companies of similar size in India.
- The tenure for the Trident Texofab management team is about average.
- Hardik's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.
misc
- Trident Texofab is not covered by any analysts.
- Trident Texofab has significant price volatility in the past 3 months.
past
- Trident Texofab has delivered over 20% year on year earnings growth in the past 5 years.
- Trident Texofab used its assets more efficiently than the IN Retail Distributors industry average last year based on Return on Assets.
- Trident Texofab has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Trident Texofab's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Trident Texofab has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Trident Texofab's 1-year earnings growth is negative, it can't be compared to the IN Retail Distributors industry average.
value
- Trident Texofab is good value based on earnings compared to the IN Retail Distributors industry average.
- Trident Texofab's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Trident Texofab's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Trident Texofab is overvalued based on assets compared to the IN Retail Distributors industry average.
- Trident Texofab is overvalued based on earnings compared to the India market.
- 540726 underperformed the Retail Distributors industry which returned -12% over the past year.
- 540726 underperformed the Market in India which returned -14.5% over the past year.
- BSE:540726 is down -19.4% underperforming the Retail Distributors industry which returned 7.5% over the past month.
- BSE:540726 is down -19.4% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800